Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis

Clinical and Experimental Dermatology

Volumn 39, Issue 6, 2014, Pages 696-707

  Meng, Y ^a   Dongmei, L ^b   Yanbin, P ^c   Jinju, F ^c   Meile, T ^c   Binzhu, L ^c   Xiao, H ^c   Ping, T ^c   Jianmin, L ^c  

^a Postgraduate School of Guangxi Medical University   (China)

^b People's Hospital of Zhangqiu   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; USTEKINUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CONFIDENCE INTERVAL; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84904445209     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12390     Document Type: Article

References (22)

1. Enamandram M, Kimball AB,. Psoriasis epidemiology: The interplay of genes and the environment. J Invest Dermatol 2013; 133: 287-9.
2. Reich K, Burden A, Eaton J, Hawkins N,. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-8.
3. Sabat R, Wolk K,. Role of IL-23, IL-17, and IL-22 in Psoriasis. In IL-17, IL-22 and Their Producing Cells. Role in Inflammation and Autoimmunity. Base l: Springer; 2013; 287-304. Available at: http://link.springer.com/chapter/10. 1007/978-3-0348-0522-3-21
4. Di Meglio P, Villanova F, Napolitano L, et al,. The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol 2013; 133: 2381-9.
5. Lowes MA, Russell CB, Martin DA, et al,. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013; 34: 174-81.
6. Reich K, Langley RG, Lebwohl M, et al,. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862-72.
7. Hsu S, Papp KA, Lebwohl MG, et al,. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148: 95.
8. Tan JY, Li S, Yang K, et al,. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis. J Dermatolog Treat 2011; 22: 323-36.
9. Feldman S,. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 2004; 15: 27-9. (Pubitemid 38252092)
10. Patel RV, Clark LN, Lebwohl M, Weinberg JM,. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 1001-17.
11. Apel M, Uebe S, Ekici A, et al,. Detection of copy number variants at new psoriasis loci identified by genomewide association studies. Oral presentation FC-1. Psoriasis: from Gene to Clinic 6th International Congress, 2011. Br J Dermatol 2011; 165: e1.
12. Elliott M, Benson J, Blank M, et al,. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci 2009; 1182: 97-110.
13. Haddix AC, Teutsch SM, Corso PS,. Prevention Effectiveness. A Guide to Decision Analysis and Economic Evaluation. Oxford: Oxford University Press, 2003.
14. Guenther L, Han C, Szapary P, et al,. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol 2011; 25: 851-7.
15. Igarashi A, Kato T, Kato M, Song M, Nakagawa H,; Japanese Ustekinumab Study G. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-2.
16. Kimball AB, Papp KA, Wasfi Y, et al,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535-45.
17. Krueger GG, Langley RG, Leonardi C, et al,. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. New Engl J Med 2007; 356: 580-2.
18. Lebwohl M, Leonardi C, Griffiths CE, et al,. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012; 66: 731-41.
19. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74. (Pubitemid 351671883)
20. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84. (Pubitemid 351671884)
21. Papp K, Griffiths C, Gordon K, et al,. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-54.
22. Tsai TF, Ho JC, Song M, et al,. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63: 154-63.